公开(公告)号：US09630956B2

公开(公告)日：2017-04-25

申请号：US13106476

申请日：2011-05-12

申请人： Jean-Damien Charrier ,  Hayley Marie Binch ,  Dennis James Hurley ,  Thomas Cleveland ,  Pramod Joshi ,  Lev Tyler Dewey Fanning ,  Joanne Pinder ,  Michael O'Donnell ,  Anisa Nizarali Virani ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  David Kay ,  Philip Michael Reaper ,  Matthew Paul Grote

发明人： Jean-Damien Charrier ,  Hayley Marie Binch ,  Dennis James Hurley ,  Thomas Cleveland ,  Pramod Joshi ,  Lev Tyler Dewey Fanning ,  Joanne Pinder ,  Michael O'Donnell ,  Anisa Nizarali Virani ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  David Kay ,  Philip Michael Reaper ,  Matthew Paul Grote

IPC分类号： A61K31/497 ,  A61K33/24 ,  C07D413/14 ,  C07D401/14 ,  C07D241/10

CPC分类号： C07D413/14

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

公开(公告)号：US20120027874A1

公开(公告)日：2012-02-02

申请号：US13106476

申请日：2011-05-12

申请人： Jean-Damien Charrier ,  Hayley Marie Binch ,  Dennis James Hurley ,  Thomas Cleveland ,  Pramod Joshi ,  Lev Tyler Dewey Fanning ,  Joanne Pinder ,  Michael O'Donnell ,  Anisa Nizarali Virani ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  David Kay ,  Philip Michael Reaper

发明人： Jean-Damien Charrier ,  Hayley Marie Binch ,  Dennis James Hurley ,  Thomas Cleveland ,  Pramod Joshi ,  Lev Tyler Dewey Fanning ,  Joanne Pinder ,  Michael O'Donnell ,  Anisa Nizarali Virani ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  David Kay ,  Philip Michael Reaper

IPC分类号： A61K31/497 ,  A61K33/24 ,  A61P35/00 ,  C07D413/14

CPC分类号： C07D413/14

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

公开(公告)号：US08877759B2

公开(公告)日：2014-11-04

申请号：US13440981

申请日：2012-09-04

申请人： Jean-Damien Charrier ,  David Kay ,  Somhairle MacCormick ,  Pierre-Henri Storck ,  Joanne Pinder ,  Michael Edward O'Donnell ,  Ronald Marcellus Alphonsus Knegtel ,  Stephen Clinton Young ,  Philip Michael Reaper ,  Steven John Durrant ,  Heather Clare Twin ,  Christopher John Davis

发明人： Jean-Damien Charrier ,  David Kay ,  Somhairle MacCormick ,  Pierre-Henri Storck ,  Joanne Pinder ,  Michael Edward O'Donnell ,  Ronald Marcellus Alphonsus Knegtel ,  Stephen Clinton Young ,  Philip Michael Reaper ,  Steven John Durrant ,  Heather Clare Twin ,  Christopher John Davis

IPC分类号： A61K31/4965 ,  C07D403/00 ,  A61K31/501 ,  A61K45/06 ,  A61K31/55 ,  A61K31/5377 ,  A61K31/7068 ,  C07D413/14 ,  C07D495/04 ,  A61K31/7048 ,  A61K33/24 ,  A61K31/497 ,  C07D453/00

CPC分类号： C07D413/14 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/555 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D453/00 ,  C07D453/02 ,  C07D495/04 ,  A61K2300/00

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式I：其中变量如本文所定义。

公开(公告)号：US09062008B2

公开(公告)日：2015-06-23

申请号：US13106337

申请日：2011-05-12

申请人： Jean-Damien Charrier ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  Anisa Nizarali Virani ,  Philip Michael Reaper ,  Joanne Pinder

发明人： Jean-Damien Charrier ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  Anisa Nizarali Virani ,  Philip Michael Reaper ,  Joanne Pinder

IPC分类号： A61K31/497 ,  A61K31/4965 ,  C07D241/20 ,  C07D401/04 ,  C07D403/04

CPC分类号： C07D241/20 ,  C07D401/04 ,  C07D403/04

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula V: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式V：其中变量如本文所定义。

公开(公告)号：US20130095193A1

公开(公告)日：2013-04-18

申请号：US13440981

申请日：2012-09-04

申请人： Jean-Damien Charrier ,  Somhairle MacCormick ,  Pierre-Henri Storck ,  Joanne Pinder ,  Michael Edward O'Donnell ,  Ronald Marcellus Alphonsus Knegtel ,  Stephen Clinton Young ,  Philip Michael Reaper ,  Steven John Durrant ,  Heather Clare Twin ,  Christopher John Davis

发明人： Jean-Damien Charrier ,  David Kay ,  Somhairle MacCormick ,  Pierre-Henri Storck ,  Joanne Pinder ,  Michael Edward O'Donnell ,  Ronald Marcellus Alphonsus Knegtel ,  Stephen Clinton Young ,  Philip Michael Reaper ,  Steven John Durrant ,  Heather Clare Twin ,  Christopher John Davis

IPC分类号： C07D413/14 ,  A61K31/5377 ,  C07D453/00 ,  C07D495/04 ,  A61K31/7068 ,  A61K45/06 ,  A61K31/501 ,  A61K31/55 ,  A61K31/7048 ,  A61K31/497 ,  A61K33/24

CPC分类号： C07D413/14 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/555 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D453/00 ,  C07D453/02 ,  C07D495/04 ,  A61K2300/00

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式I：其中变量如本文所定义。

公开(公告)号：US20120035408A1

公开(公告)日：2012-02-09

申请号：US13106337

申请日：2011-05-12

申请人： Jean-Damien Charrier ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  Anisa Nizarali Virani ,  Phillip Michael Reaper ,  Joanne Pinder

发明人： Jean-Damien Charrier ,  Steven John Durrant ,  Stephen Clinton Young ,  Pierre-Henri Storck ,  Anisa Nizarali Virani ,  Phillip Michael Reaper ,  Joanne Pinder

IPC分类号： A61N5/00 ,  A61K31/4965 ,  A61P35/00 ,  A61K31/497 ,  C07D401/04 ,  C07D241/20 ,  C07D403/04

CPC分类号： C07D241/20 ,  C07D401/04 ,  C07D403/04

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula V: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式V：其中变量如本文所定义。

公开(公告)号：US20130034616A1

公开(公告)日：2013-02-07

申请号：US13531467

申请日：2012-06-22

申请人： Pierre-Henri Storck ,  Jean-Damien Charrier ,  Alistair Rutherford ,  Michael Paul Mortimore ,  Somhairle MacCormick ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant

发明人： Pierre-Henri Storck ,  Jean-Damien Charrier ,  Alistair Rutherford ,  Michael Paul Mortimore ,  Somhairle MacCormick ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant

IPC分类号： A61K31/4985 ,  A61K31/5377 ,  A61K31/7048 ,  A61K33/24 ,  A61P35/00 ,  C07D487/04 ,  A61K31/551

CPC分类号： C07D487/04

摘要： The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

公开(公告)号：US20130018035A1

公开(公告)日：2013-01-17

申请号：US13531461

申请日：2012-06-22

申请人： Somhairle MacCormick ,  Pierre-Henri Storck ,  Michael Paul Mortimore ,  Jean-Damien Charrier ,  Ronald Knegtel ,  Stephen Clinton Young ,  Joanne Pinder ,  Steven John Durrant

发明人： Somhairle MacCormick ,  Pierre-Henri Storck ,  Michael Paul Mortimore ,  Jean-Damien Charrier ,  Ronald Knegtel ,  Stephen Clinton Young ,  Joanne Pinder ,  Steven John Durrant

IPC分类号： A61K31/4985 ,  A61P35/00 ,  C07D487/04

CPC分类号： C07D487/04

摘要： The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

公开(公告)号：US09309250B2

公开(公告)日：2016-04-12

申请号：US13531467

申请日：2012-06-22

申请人： Pierre-Henri Storck ,  Jean-Damien Charrier ,  Alistair Rutherford ,  Michael Paul Mortimore ,  Somhairle MacCormick ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant

发明人： Pierre-Henri Storck ,  Jean-Damien Charrier ,  Alistair Rutherford ,  Michael Paul Mortimore ,  Somhairle MacCormick ,  Ronald Marcellus Alphonsus Knegtel ,  Steven John Durrant

IPC分类号： A61K31/4985 ,  C07D241/38 ,  C07D487/04

CPC分类号： C07D487/04

摘要： The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡咯并吡嗪化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式I：其中变量如本文所定义。

公开(公告)号：US08822469B2

公开(公告)日：2014-09-02

申请号：US13531461

申请日：2012-06-22

申请人： Somhairle MacCormick ,  Pierre-Henri Storck ,  Michael Paul Mortimore ,  Jean-Damien Charrier ,  Ronald Knegtel ,  Stephen Clinton Young ,  Joanne Pinder ,  Steven John Durrant

发明人： Somhairle MacCormick ,  Pierre-Henri Storck ,  Michael Paul Mortimore ,  Jean-Damien Charrier ,  Ronald Knegtel ,  Stephen Clinton Young ,  Joanne Pinder ,  Steven John Durrant

IPC分类号： A61K31/4985 ,  C07D241/36

CPC分类号： C07D487/04

摘要： The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡咯并吡嗪化合物。 本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。 本发明的化合物具有式I：其中变量如本文所定义。